Sinopharm Group Co. Ltd.

DB:X2S Stock Report

Market Cap: €8.5b

Sinopharm Group Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Wanyong Lian

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownershipn/a
Management average tenure3.8yrs
Board average tenure4.3yrs

Recent management updates

Recent updates

CEO

Wanyong Lian (53 yo)

less than a year

Tenure

Mr. Wanyong Lian has been the Head of the investment management department of CNPGC since February 2008. Mr. Lian has over 20 years of working experience, all of which is management experience. Mr. Lian wa...

Leadership Team

NamePositionTenureCompensationOwnership
Wanyong Lian
President & Executive Directorless than a yearno datano data
Xiaojuan Li
Chief Financial Officer3.8yrsno datano data
Yijian Wu
Secretary to the Board6yrsno datano data

3.8yrs

Average Tenure

53yo

Average Age

Experienced Management: X2S's management team is considered experienced (3.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Wanyong Lian
President & Executive Directorless than a yearno datano data
Qiyu Chen
Non-Executive Vice Chairman14.6yrsno datano data
Dongjiu Li
Non-Executive Director3.5yrsno datano data
Xiaohui Guan
Chief Supervisor3.5yrsno datano data
Tak Lung Wu
Independent Non-Executive Director4.3yrsCN¥350.00kno data
Peiyu Li
Independent Non-Executive Director4.3yrsCN¥350.00kno data
Bingxiang Zhao
Non-Executive Chairmanless than a yearno datano data
Deyong Wen
Non-Executive Director7.3yrsno datano data
Fangruo Chen
Independent Non-Executive Director6yrsCN¥350.00kno data
Rongli Feng
Non Executive Director4.5yrsno datano data
Weifeng Yu
Independent Non-Executive Director4.3yrsCN¥350.00kno data
Peng Wang
Non-executive Director1.3yrsno datano data

4.3yrs

Average Tenure

53yo

Average Age

Experienced Board: X2S's board of directors are considered experienced (4.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 01:05
End of Day Share Price 2024/12/23 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sinopharm Group Co. Ltd. is covered by 43 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason MannBarclays
Derrick SunBNP Paribas Securities (Asia)
Bo LiBofA Global Research